ProCE Banner Activity

KEYNOTE-355: Randomized, Placebo-Controlled Phase III of Pembrolizumab + Chemotherapy in Previously Untreated Metastatic TNBC (Final Results)

Slideset Download
Conference Coverage

Addition of pembrolizumab to chemotherapy improved both OS and PFS in patients with locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 CPS ≥10.

Released: September 28, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc